ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 30.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 192,448 shares of the company’s stock after selling 82,841 shares during the quarter. Dimensional Fund Advisors LP owned 0.20% of ARS Pharmaceuticals worth $1,638,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SPRY. Russell Investments Group Ltd. purchased a new position in ARS Pharmaceuticals during the 1st quarter worth approximately $60,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ARS Pharmaceuticals by 151.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after buying an additional 4,472 shares in the last quarter. Principal Financial Group Inc. acquired a new position in ARS Pharmaceuticals during the second quarter valued at $87,000. Paloma Partners Management Co purchased a new stake in ARS Pharmaceuticals in the 1st quarter worth about $103,000. Finally, SG Americas Securities LLC acquired a new stake in ARS Pharmaceuticals during the 1st quarter worth about $119,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on SPRY shares. Raymond James upgraded ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $18.00 to $22.00 in a report on Tuesday, August 13th. William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday. Finally, Leerink Partners upped their price target on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research note on Friday, September 20th. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, ARS Pharmaceuticals currently has an average rating of “Buy” and an average price target of $24.00.

ARS Pharmaceuticals Price Performance

Shares of SPRY stock opened at $14.52 on Friday. ARS Pharmaceuticals, Inc. has a fifty-two week low of $3.35 and a fifty-two week high of $16.50. The stock’s 50-day moving average is $13.02 and its two-hundred day moving average is $10.60. The firm has a market cap of $1.41 billion, a P/E ratio of -27.92 and a beta of 0.91.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $2.00 million. As a group, research analysts expect that ARS Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Richard E. Lowenthal sold 100,000 shares of the stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $11.40, for a total transaction of $1,140,000.00. Following the transaction, the chief executive officer now owns 1,547,447 shares of the company’s stock, valued at approximately $17,640,895.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Kathleen D. Scott sold 12,500 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $16.00, for a total transaction of $200,000.00. Following the transaction, the chief financial officer now owns 13,199 shares of the company’s stock, valued at approximately $211,184. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Richard E. Lowenthal sold 100,000 shares of the stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $11.40, for a total value of $1,140,000.00. Following the transaction, the chief executive officer now directly owns 1,547,447 shares in the company, valued at approximately $17,640,895.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,043,395 shares of company stock valued at $14,071,032 in the last three months. Insiders own 40.10% of the company’s stock.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.